Parameter
| Biomarker | ASXL1 mutation | Full name | Additional Sex Combs Like 1 gene mutation | Molecular Type | Nucleic acid (gene) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognosis and prediction of treatment response |
| Disease | Chronic Myeloid Leukemia(CML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Patient samples (direct sequencing, qRT-PCR) | ||
| Pathobiological Mechanisms | Mutant patients exhibit significantly increased risks of drug resistance and disease progression, which are correlated with the Sokal risk score. | ||||
| Clinical Availability Status | Research verification: 11.25% of patients exhibited mutations, which were associated with ABL1 KD mutations. | ||||
| Notes and Dynamics | Can assist in formulating the optimal TKI regimen to prevent disease progression. | ||||